Personalized antiplatelet therapy according to CYP2C19 genotype after percutaneous coronary intervention: A randomized control trial

Benefits of laboratory personalized antiplatelet therapy in patients undergoing percutaneous coronary intervention: A meta-analysis of randomized controlled trials

“…Among them, 14 studies [11][12][13][14][15][16][17][18][19][20][21][22][23][24] reporting the differences in terms of MACEs and bleeding events between 9497 patients with and without the PAPT were considered eligible for our meta-analysis (4878 randomized to PAPT and 4619 to control) (Fig. 1).…”

Are Genetic Tests for Atherosclerosis Ready for Routine Clinical Use?

“…115 Two point-of-care testing systems are currently FDA-approved and reimbursable through Medicare. Crucially, although there is retrospective and other observational evidence that genetic information may improve outcomes, [116][117][118] there is a lack of completed prospective evidence examining the benefit of testing for CYP2C19 genotype in the context of the newer, more potent alternative P2Y 12 inhibitors, prasugrel or ticagrelor. The pharmacology of these new drugs is not influenced by CYP2C19 variation but they carry higher bleeding risk and greater cost because of patent protection.…”

Future Translational Applications From the Contemporary Genomics Era

“…We are just beginning to see evidence in this regard, with 2 studies reported in late 2013. Xie and colleagues 78 published a small study in 600 patients receiving percutaneous coronary intervention from China who were randomized to genotype-guided treatment versus conventional therapy. The composite end point of major adverse coronary events at 180 days was 2.6% in the CYP2C19 genotype–guided arm and 9.03% in the conventional arm ( P =0.001), with lower rates of death, MI, and stent thrombosis but not stroke.…”